Document:

EX-10.2

 Exhibit 10.2 
 SECOND AMENDED AND RESTATED 
 STOCKHOLDERS’ AGREEMENT 

THIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Agreement”) is made and entered into
as of December 28, 2012, by and among ARATANA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the holders of Series C Preferred Stock (as defined below) listed on Exhibit A
hereto (the “Series C Preferred Holders”), each of the holders of Series B Preferred Stock (as defined below) listed on Exhibit B hereto (the “Series B Preferred
Holders”), each of the holders of Series A Preferred Stock (as defined below) listed on Exhibit C hereto (the “Series A Preferred Holders”), each of the holders of Series A-1 Preferred
Stock (as defined below) listed on Exhibit D hereto (the “Series A-1 Preferred Holders” and, together with the Series B Preferred Holders and the Series A Preferred Holders, the
“Preferred Holders”), each of the holders of Common Stock (as defined below) listed on Exhibit E hereto (the “Common Holders” and collectively with the Series A Preferred Holders and
the Series A-1 Preferred Holders, the “Existing Holders”) and each Additional Holder (as defined below) who shall, after the date hereof, acquire shares of Common Stock and become a party to this Agreement as a
“Common Holder” by executing and delivering to the Company an Instrument of Accession in the form of Exhibit F hereto. The Common Holders (including any Additional Holders) and the Preferred Holders are sometimes refereed to
herein individually as a “Stockholder” and collectively as the “Stockholders”. 

RECITALS 

WHEREAS, the Company and the Series A Preferred Holders are parties to that certain Series A Preferred Stock Purchase
Agreement, dated as of December 27, 2010 (the “Series A Purchase Agreement”), and the Company and the Series A-1 Preferred Holders are parties to that certain Series A-1 Preferred Stock Purchase Agreement,
dated as of December 27, 2010 (the “Series A-1 Purchase Agreement” and, together with the Series A Purchase Agreement, the “Prior Purchase Agreements”); 

WHEREAS, as a condition of entering into the Prior Purchase Agreements, the Existing Holders and the Company executed that certain
Stockholders’ Agreement dated as of December 27, 2010 among the Company and the Existing Holders (the “Prior Agreement”); 
 WHEREAS, the Series B Preferred Holders are parties to that certain Series B Preferred Stock Purchase Agreement, dated as of November 1, 2011, among the Company and the Series B
Preferred Holders (the “Series B Purchase Agreement”); 
 WHEREAS, as a condition of
entering into the Series B Purchase Agreement the Series B Preferred Holders, the Existing Holders and the Company executed that certain First Amended and Restated Stockholders’ Agreement, dated as of November 1, 2011 (the
“Restated Prior Agreement”); 
 WHEREAS, the Series C Preferred Holders are parties to that
certain Series C Preferred Stock Purchase Agreement of even date herewith among the Company and the Series C Preferred Holders (the “Series C Purchase Agreement”); and 

 WHEREAS, the Series C Preferred Holders have requested that the Company and
Series B Preferred Holders and Existing Holders representing at least the Majority Investors (as defined in the Restated Prior Agreement) amend and restate the Restated Prior Agreement as set forth below, as an inducement to the Series C
Preferred Holders to enter into the Series C Purchase Agreement. 
 NOW THEREFORE, in consideration of the foregoing
recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Series B Preferred Holders and
the Existing Holders hereby agree that the Restated Prior Agreement shall be amended and restated, and the parties to this Agreement further agree as follows: 
 AGREEMENT 
 1. CERTAIN DEFINITIONS. For purposes of this Agreement: 

1.1 The term “Avalon Major Investor” shall mean, collectively, Avalon Ventures IX, L.P. and each Permitted
Transferee (as defined below) thereof. 
 1.2 The term “Certificate of Incorporation” shall mean
that certain Third Amended and Restated Certificate of Incorporation of the Company of even date herewith. 
 1.3 The
term “Company Transaction” shall mean any: (i) acquisition of the Company by another entity or person unaffiliated with any Stockholder by means of any transaction or series of related transactions (including, without
limitation, any reorganization, merger, consolidation, tender offer or stock sale) that results in the transfer of at least a majority of the then-outstanding voting power of the Company; or (ii) sale of all or substantially all of the assets
of the Company to an entity or person unaffiliated with any Stockholder. 
 1.4 The term “Major
Holders” shall have the meaning set forth in that certain Second Amended and Restated Investors’ Rights Agreement, dated as of even date herewith, by and among the Company and the investors named therein. 

1.5 The term “Majority Investors” shall mean and include the Avalon Major Investor and the MPM Major
Investor; provided, however, that to the extent that any of the foregoing ceases to hold shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock, such entity shall no longer be a Majority
Investor. 
 1.6 The term “Major Series B Subject Holders” shall mean Subject Holders who
hold at least 333,333 shares of Series B Preferred Stock. 
 1.7 The term “Major Series C Subject
Holders” shall mean Subject Holders who hold at least 250,000 shares of Series C Preferred Stock. 
 1.8
The term “MPM Major Investor” shall mean, collectively, MPM BioVentures V, L.P. and each Permitted Transferee thereof. 

  
 2 

 1.9 The term “Restricted Holder” shall mean and include the
Common Holders (including any Additional Holders), the Subject Holders (as defined below) and the Series A-1 Preferred Holders. 
 1.10 The term “Series A Directors” shall mean and includes the Avalon Director (as defined below), the MPM Director (as defined below) and the Additional Series A
Director (as defined below). 
 1.11 The term “Subject Holders” shall mean the Series C
Preferred Holders who are not Existing Holders or affiliates of Existing Holders and the Series B Preferred Holders who are not Existing Holders or affiliates of Existing Holders. 
 2. VOTING OF STOCKHOLDER SHARES. 
 2.1 Shares Held Subject to
Agreement. Each of the Stockholders agrees to hold all shares of capital stock of the Company registered in its respective name or beneficially owned by it as of the date hereof and any and all other securities of the Company legally or
beneficially acquired by it after the date hereof, including, without limitation, any shares of capital stock issuable upon exercise or conversion of securities exercisable for or convertible into shares of the Company’s capital stock
(hereinafter collectively referred to as the “Stockholder Shares”) subject to, and, at any time when entitled, to vote the Stockholder Shares in accordance with, the provisions of this Section 2. 

2.2 Size of Board of Directors. Subject to Section 2.3(a), each Stockholder shall, at all times when entitled to vote or give
a written consent with respect to such matter, vote at all regular or special meetings of stockholders, and shall give written consent with respect to, all Stockholder Shares so as to set and maintain the number of authorized directors comprising
the Company’s Board of Directors (the “Board of Directors”) at seven (7) directors. 
 2.3
Election of Directors. 
 (a) At each election of directors in which the holders of the Company’s Common Stock
(the “Common Stock”), the holders of the Company’s Series C Preferred Stock (the “Series C Preferred Stock”), the holders of the Company’s Series B Preferred Stock (the
“Series B Preferred Stock”), the holders of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”) and/or the holders of the Company’s Series A-1
Preferred Stock (the “Series A-1 Preferred Stock” ), whether voting together as a single class or each voting as a separate class, are entitled to elect directors of the Company, the Stockholders shall, at all times when
entitled to vote or give a written consent with respect to, vote (or shall consent to vote pursuant to an action by written consent of the holders of capital stock of the Company) all of their respective Stockholder Shares so as to elect:

 (i) for so long as the Avalon Major Investor is a Majority Investor, one (1) designee of the Avalon Major
Investor (the “Avalon Director”), which designee shall initially be Jay Lichter, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the then-outstanding shares of
Series A Preferred Stock, voting as a separate class; 

  
 3 

 (ii) for so long as the MPM Major Investor is a Majority Investor, one
(1) designee of the MPM Major Investor (the “MPM Director”), which designee shall initially be John Vander Vort, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the
then-outstanding shares of Series A Preferred Stock, voting as a separate class; 
 (iii) one (1) designee
that is designated by the holders of at least seventy-five percent (75%) of the then-outstanding shares of Series A Preferred Stock (the “Additional Series A Director”), which designee shall initially be Ron
Meeusen, to serve as one (1) of the three (3) directors to be elected by the holders of a majority of the then-outstanding shares of Series A Preferred Stock, voting as a separate class; 

(iv) one (1) designee that is designated by the holders of a majority of the then-outstanding shares of Series C
Preferred Stock and Series B Preferred Stock, voting together as a single class on an as-if-converted to Common Stock basis (the “Series B/C Director”) to serve as one (1) of the remaining directors, which
designee shall initially be Linda Rhodes; 
 (v) one (1) designee that is designated by the holders of a majority
of the then-outstanding shares of Common Stock held by the Common Holders, which designee shall in all cases be the person serving as the Chief Executive Officer of the Company (the “CEO Director”), which shall initially be
Steven St. Peter, to serve as one (1) of the remaining directors; and 
 (vi) other designees that are acceptable
to a majority of the Series A Directors as independent members of the Board of Directors (the “Independent Directors”), which designees shall initially be Craig Tooman and Rip Gerber, to serve as the remaining directors.

 (b) Any vote taken to remove any director elected pursuant to this Section 2.3, or to fill any vacancy created by
the resignation, removal or death of a director elected pursuant to this Section 2.3, shall also be subject to the provisions of this Section 2.3. 
 (c) None of the parties hereto and no officer, director, stockholder, partner, employee or agent of any such party makes any representation or warranty as to the fitness or competence of the
nominee of any party hereunder to serve on the Board of Directors by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this Agreement. 

(d) The Company agrees that it shall, at the request of any Stockholder or group of Stockholders entitled to designate directors
pursuant to Section 2.3(a), promptly take all actions necessary (pursuant to the Company’s bylaws, the laws of the State of Delaware or otherwise) to call and conduct a special meeting of the stockholders of the Company for the purpose of
electing directors in accordance with the provisions of Section 2.3(a). 
 2.4 Drag Along. 

(a) In the event that the Board of Directors and the Majority Investors approve any Company Transaction, each Stockholder will
vote (to the extent such Stockholder is entitled 

  
 4 

 
to vote) for, consent to and raise no objections to such Company Transaction. Each Stockholder will waive any dissenter’s rights, appraisal rights or similar rights, to the extent
applicable, in connection with any such Company Transaction. If the Company Transaction is structured as a sale of stock, each Stockholder will agree to sell all of its Stockholder Shares and rights to acquire Stockholder Shares pursuant to the
terms and conditions approved by the Board of Directors and the Majority Investors. Each Stockholder will take all necessary or desirable actions in connection with the consummation of the Company Transaction as requested by the Board of Directors
and the Majority Investors including, without limitation, delivering such Stockholder’s stock certificates free and clear of all liens and encumbrances (other than those arising under applicable securities laws). 

(b) Notwithstanding the foregoing Section 2.4(a), a Stockholder will not be required to comply with Section 2.4(a) in
connection with any Company Transaction unless: 
 (i) any representations and warranties to be made by such Stockholder
in connection with the Company Transaction are limited to representations and warranties related to authority, ownership and the ability to convey title to such Stockholder Shares, including but not limited to representations and warranties that:
(w) the Stockholder holds all right, title and interest in and to the Stockholder Shares such Stockholder purports to hold, free and clear of all liens and encumbrances; (x) the obligations of the Stockholder in connection with the Company
Transaction have been duly authorized, if applicable; (y) the documents to be entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance
with their respective terms; and (z) neither the execution and delivery of documents to be entered into in connection with the Company Transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or
violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency; 
 (ii)
the Stockholder shall not be liable for the inaccuracy of any representation or warranty made by any other individual or entity (other than the Company) in connection with the Company Transaction; 

(iii) the liability for indemnification, if any, of such Stockholder in the Company Transaction and for the inaccuracy of any
representations and warranties made by the Company or breaches by the Company of its covenants made in any acquisition agreement in connection with such Company Transaction, is several and not joint with any other individual or entity and is pro
rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such Company Transaction; and 
 (iv) The consideration paid to the Stockholders will be distributed pursuant to Section 3 of the Certificate of Incorporation, as if such Company Transaction were an Acquisition. 

2.5 Vote to Increase Authorized Common Stock. Each Stockholder shall, at all times when entitled to vote with respect to such
matter, vote (or shall, at all times when entitled to vote with respect to such matter, consent to vote pursuant to an action by written consent of the holders of capital stock of the Company) all of its respective Stockholder Shares as shall be

  
 5 

 
necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there are sufficient shares of Common Stock available for conversion of all of the shares of
Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock outstanding at any such time. 
 2.6 Irrevocable Proxy. Each Stockholder hereby constitutes and appoints the CEO Director as the attorney and proxy of such Stockholder, with full power of substitution, with respect to the matters
set forth in this Section 2, and hereby authorizes the CEO Director to represent and to vote all of the Stockholder Shares held by such Stockholder in accordance with the provisions set forth in this Section 2; provided,
however, that such proxy shall be in effect and exercisable if and only if the Stockholder granting such proxy: (i) fails to vote altogether on a matter covered by this Section 2; or (ii) attempts to vote on a matter covered by
this Section 2 in a manner other than as provided by this Section 2. The proxy granted pursuant to this Section 2.6 is coupled with an interest and shall be irrevocable unless and until the provisions of this Section 2 terminate
pursuant to the provisions of Section 2.7 below. Each Stockholder hereby revokes any and all previous proxies granted with respect to the Stockholder Shares held by such Stockholder and agrees not to grant any other proxy or power of attorney
with respect to such Stockholder Shares or to deposit any of such Stockholder Shares into a voting trust or to enter into any similar agreement, arrangement or understanding with any other person with respect to the voting of any Stockholder Shares
held by such Stockholder unless and until the provisions of this Section 2 terminate pursuant to the provisions of Section 2.7 below. 
 2.7 Termination of Voting Provisions. The provisions of this Section 2 shall continue in full force and effect from the date hereof through the earliest of the following dates, on which date
such provisions shall terminate and cease to be in effect: (i) the date of the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration statement filed with the Securities and Exchange Commission (the
“SEC”) and declared effective under the Securities Act of 1933, as amended (the “Securities Act”); or (ii) the date of the closing of a sale, lease or other disposition of all or substantially all
of the Company’s assets or the Company’s merger into or consolidation with any other corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior
to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this
clause “(ii)” shall not apply to a merger effected exclusively for the purpose of changing the domicile of the Company. 
 3.
RESTRICTIONS ON TRANSFERS BY STOCKHOLDERS. 
 3.1 General Restriction. Each Restricted Holder agrees that such
Restricted Holder shall not sell, assign, transfer, pledge, hypothecate, mortgage or dispose of, by gift or otherwise, or in any way encumber (collectively, “Transfer”), all or any part of the Stockholder Shares held by such
Stockholder other than in compliance with Sections 3.2 and 3.3 below. 

  
 6 

 3.2 Right of First Refusal. 

(a) Subject to Section 3.8 below, if at any time any Restricted Holder desires to Transfer in any manner any Stockholder
Shares held by such Restricted Holder pursuant to the terms of a bona fide written offer received from a third party (the “Restricted Holder Buyer”), such Restricted Holder (the “Selling Restricted
Holder”) shall submit a written offer (the “Restricted Holder Offer”) to sell such Stockholder Shares (the “Offered Stockholder Shares”) to the Company at the same price and on the same
terms and conditions on which the Selling Restricted Holder proposes to sell such Offered Stockholder Shares to the Restricted Holder Buyer. The Restricted Holder Offer shall disclose the identity of the proposed Restricted Holder Buyer, the number
of Offered Stockholder Shares, the terms of the proposed Transfer, including price, and any other material facts, terms and conditions relating to the proposed Transfer. Within thirty (30) days after receipt of the Restricted Holder Offer, the
Company shall give notice to the Selling Restricted Holder of its intent to purchase all or a portion of the Offered Stockholder Shares from the Selling Restricted Holder on the terms and conditions set forth in the Restricted Holder Offer. Such
notice shall specify the time, place and date for settlement of such purchase, which shall be consummated at a closing held at the Company within the thirty (30) day period specified above. 

(b) If the Company does not elect to purchase all of the Offered Stockholder Shares as provided in Section 3.2(a), the
Company shall, within five (5) days after expiration of the thirty (30) day period specified in Section 3.2(a), provide each Major Holder with written notice (the “ROFR Notice”) of such election, which ROFR
Notice shall include a copy of the Restricted Holder Offer provided to the Company pursuant to Section 3.2(a). Each Major Holder shall then have the right, exercisable within thirty (30) days following receipt of the ROFR Notice, to
purchase up to that number of the Offered Stockholder Shares that the Company elected not to purchase from such Selling Restricted Holder (all such remaining shares being referred to as the “Remaining Offered Stockholder
Shares”) equal to the aggregate Remaining Offered Stockholder Shares multiplied by a fraction: (i) the numerator of which is the number of Stockholder Shares held by such Major Holder; and (ii) the denominator of which is the
aggregate number of Stockholder Shares held by all of the Major Holders (such amount to be referred to as a Major Holder’s “Major Holder ROFR Pro Rata Share”). In the event that a Major Holder does not wish to purchase
its full Major Holder ROFR Pro Rata Share, then any Major Holder who has elected to purchase its full Major Holder ROFR Pro Rata Share shall have the right to purchase, on a pro rata basis with any other Major Holders who so elect, any Remaining
Offered Stockholder Shares not purchased. If exercised by the Major Holders pursuant hereto, the right to purchase the Offered Stockholder Shares or the Remaining Offered Stockholder Shares, as the case may be, shall be exercised by written notice,
signed by the Company and the participating Major Holders, and delivered to the Selling Restricted Holder prior to the expiration of the thirty (30) day notice period specified above. Such notice shall specify the time, place and date for
settlement of such purchase, which shall be consummated at a closing held at the Company within ten (10) days after the expiration of the thirty (30) day notice period specified above. 

(c) For the purposes of this Section 3.2, the number of Stockholder Shares held by a Major Holder shall include the holdings
of Permitted Transferees of such Major Holder, and such holdings shall be aggregated together with that of such Major Holder. As used 

  
 7 

 
in this Agreement, the term “Permitted Transferee” means: (i) in the case of a Stockholder that is a partnership, any constituent partner of such partnership and any
affiliated partnership, limited liability company or other entity managed by the same management company or general partner or any affiliate of such management company or general partner; (ii) in the case of a Stockholder that is a limited
liability company, any member of such limited liability company and any affiliated limited liability company, partnership or other entity managed by the same management company or member or any affiliate of such management company or member;
(iii) in the case of a Stockholder that is an individual, the spouse, children, grandchildren or spouse of such children or grandchildren of such person or to trusts for the benefit of such person or such person’s spouse, children,
grandchildren or spouse of such children or grandchildren; (iv) in the case of a Stockholder that is a trust, any beneficiary of such trust; (v) in the case of the Kansas Bioscience Authority (or its successor or replacement entity), any
successor or replacement entity formed by or as an instrumentality or authority of the State of Kansas; (vi) in the case of the Ewing Marion Kauffman Foundation (or its successor or replacement entity), to any successor or replacement entity
formed by the Ewing Marion Kauffman Foundation for the purpose of holding equity investments, or any entity under common investment management with any such successor or replacement entity; and (vii) in the case of a Company Transaction
approved by the Board of Directors and the Majority Investors pursuant to Section 2.4, the transferee approved by the Board of Directors and the Majority Investors pursuant to the terms and conditions approved by the Board of Directors and the
Majority Investors. 
 (d) Except as set forth in Section 3.8 below, in the event that the Company and the Major
Holders, on a collective basis, do not elect to purchase all of the Offered Stockholder Shares pursuant to and within the time periods set forth above, then the Company and the Stockholders shall be deemed to have forfeited any right to purchase the
Offered Stockholder Shares, and, subject to Section 3.3 and Section 3.8, the Selling Restricted Holder shall be free for a period of sixty (60) days thereafter, to sell all, but not less than all, of the Offered Stockholder Shares to
the Restricted Holder Buyer, if the Restricted Holder Buyer agrees in writing to be bound by the terms of this Agreement in the same capacity as the Selling Restricted Holder. Any such Transfer shall be at the same price per share, and upon the same
terms and conditions, as specified in the Restricted Holder Offer. Any Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter again be subject to the requirements of this Section 3.2. 

3.3 Right of Co-Sale. If at any time any Selling Restricted Holder desires to Transfer in any manner any Stockholder Shares
pursuant to the terms of a Restricted Holder Offer received from a Restricted Holder Buyer, then each Major Holder shall have the right (the “Right of Co-Sale”) to require, as a condition to the Transfer, that the Restricted
Holder Buyer purchase from such Major Holder, at the same price per share and on the same terms and conditions as involved in such sale or disposition by the Selling Restricted Holder, that percentage of Stockholder Shares owned by such Major Holder
equal to a fraction: (i) the numerator of which is the number of Stockholder Shares held by such Major Holder; and (ii) the denominator of which is the sum of (a) the aggregate number of Stockholder Shares held by the Major Holders
and (b) the aggregate number of Stockholder Shares then held by the Selling Restricted Holder (such percentage hereinafter referred to as a Major Holder’s “Co-Sale Pro Rata Percentage”). To the extent that a Major
Holder does not exercise its Right of Co-Sale or elects to sell less than its full Co-Sale Pro Rata Percentage pursuant to this Section 3.3, the 

  
 8 

 
Selling Restricted Holder shall be entitled to sell to the Restricted Holder Buyer, at any time within sixty (60) days of the expiration of the rights granted pursuant to Section 3.2
and this Section 3.3, on the terms set forth in the Restricted Holder Offer, that number Stockholder Shares determined based on the portion of such Stockholder’s Co-Sale Pro Rata Percentage not sold pursuant to this Section 3.3. Any
Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter again be subject to the requirements of this Section 3.3. 
 3.4 Exceptions to Restrictions. The restrictions on a Restricted Holder’s ability to Transfer Stockholder Shares contained in this Section 3 shall not apply to: (i) any Transfer of
Stockholder Shares by a Stockholder to any Permitted Transferee; or (ii) any Transfer of Stockholder Shares to the Company (or any assignee of the Company) pursuant to the terms of a stock restriction or stock repurchase agreement approved by
the Board of Directors which provides for such sale upon the termination of a Stockholder’s service with the Company. In the event of any Transfer pursuant to the foregoing clause “(i)”, the Permitted Transferee of the Stockholder
Shares shall hold the Stockholder Shares so acquired with all the rights conferred by, and subject to all the restrictions imposed by, this Agreement and such Permitted Transferee shall agree in writing to be bound by the terms of this Agreement in
the same capacity as the Stockholder. 
 3.5 Termination. The restrictions on a Restricted Holder’s ability to
Transfer Stockholder Shares contained in this Section 3 shall terminate upon the earlier of: (i) the date of the closing of a firmly underwritten public offering of the Common Stock pursuant to a registration statement filed with the SEC
and declared effective under the Securities Act; or (ii) the date of the closing of a sale, lease, or other disposition of all or substantially all of the Company’s assets or the Company’s merger into or consolidation with any other
corporation or other entity, or any other corporate reorganization, in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than
fifty percent (50%) of the voting power of the corporation or other entity surviving such transaction; provided, however, that this clause “(ii)” shall not apply to a merger effected exclusively for the purpose of
changing the domicile of the Company. 
 3.6 Additional Holders. As a condition to the issuance by the Company to any
individual or entity (each, an “Additional Holder”) of Stockholder Shares (or rights or options to acquire Stockholder Shares), the Company shall require such Additional Holder to become a party to this Agreement as an
additional “Series C Preferred Holder,” “Series B Preferred Holder,” “Series A Preferred Holder,” “Series A-1 Preferred Holder” or “Common Holder,” as applicable, hereunder via
the execution and delivery to the Company of an Instrument of Accession in the form attached hereto as Exhibit F. 

3.7 “Market Stand-Off” Agreement. Each Stockholder hereby agrees that such Stockholder shall not sell, transfer, make
any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Stockholder Shares held by such Stockholder (other than those included in the registration) for a
period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days (or such other period as may be requested by the Company or an underwriter to
accommodate regulatory restrictions on (1) the 

  
 9 

 
publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto), following the effective date of a registration statement of the Company filed under the Securities Act relating to the initial public offering of shares of Common Stock registered
under the Securities Act; provided, however, that all officers and directors of the Company and Stockholders of at least one percent (1%) of the Company’s voting securities enter into similar agreements. The Company may
impose stop-transfer instructions with respect to any Stockholder Shares subject to the foregoing restriction until the end of such one hundred eighty (180) day period (or such other period as may be requested by the Company or an underwriter
to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or
NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). Each Stockholder agrees that any transferee of any Stockholder Shares shall be bound by this Section 3.7. The underwriters of the Company’s stock are intended
third-party beneficiaries of this Section 3.7 and shall have the right, power and authority to enforce the provisions hereof as though they were parties hereto. Any discretionary waiver or termination of the restrictions of any or all of such
agreements by the Company or the underwriters shall apply pro rata to all Stockholders subject to such agreements, based on the number of Stockholder Shares subject to such agreements. 

3.8 Additional Restrictions on Subject Holders. No Subject Holder may Transfer all or any part of the Series C Preferred
Stock or the Series B Preferred Stock held by such Subject Holder prior to December 31, 2014 (the “Trigger Date”), except in the case of a Transfer to a Permitted Transferee; provided, however, that, upon the
Company’s receipt of prior written notice thereof from the Subject Holder, the Board of Directors may approve or reject a proposed Transfer other than to a Permitted Transferee prior to the Trigger Date in its sole discretion. On and after the
Trigger Date (or prior to the Trigger Date with the approval of the Board of Directors pursuant to the immediately preceding sentence), each Subject Holder may Transfer all or any part of its Series C Preferred Stock or Series B Preferred
Stock by following the procedure described in Section 3.2 above; provided, however, that notwithstanding Section 3.2(d) above, in the event that the Company and the Major Holders, on a collective basis, do not elect to purchase all of the
Offered Stockholder Shares pursuant to and within the time periods set forth in Section 3.2, then the provisions of Section 3.2(d) shall not apply but, instead, the Subject Holder may submit a written request to the Board of Directors for
its approval of the Restricted Holder Offer containing the information required to be contained in the Restricted Holder Offer pursuant to Section 3.2(a) above and any other information that may be reasonably required by the Board of Directors
(the “Request”) and thereafter, subject to Section 3.3, may Transfer the remaining Offered Stockholder Shares to the Restricted Holder Buyer only if the Board of Directors has issued to the Subject Holder a written
consent to such Request (the “Consent”) and then only in accordance with the terms of the Consent and of this Agreement. The Board of Directors may withhold or delay such Consent for reasonable business reasons for a period
of up to twelve (12) months following the submission of the Request. Any Consent shall lapse sixty (60) days after the date of the Consent. Any Offered Stockholder Shares not sold within such sixty (60) day period shall thereafter
again by subject to the requirements of this Section 3.8. 

  
 10 

 3.9 Option Upon Involuntary Transfer. Each Subject Holder or its
legal representative shall notify the Company in writing (the “Involuntary Transfer Notice”) promptly upon the occurrence, or any event that may lead to the occurrence, of an involuntary Transfer of all or a portion of its
Stockholder Shares (the “Involuntary Transfer Shares”) by operation of law to any person other than to the Company or the Major Holders in accordance with this Section 3 (including, without limitation, to a
Stockholder’s trustee in bankruptcy, to a purchaser at a creditor’s or court sale, pursuant to the death of a Stockholder, pursuant to a divorce, or to the guardian or conservator of an incompetent or incapacitated Stockholder) (an
“Involuntary Transfer”). The Company shall have the option to purchase all or a portion of the Involuntary Transfer Shares by delivering notice of its election to exercise such option to the person to whom the Involuntary
Transfer Shares were, or are to be, Transferred (the “Involuntary Transferee”) within thirty (30) days after its receipt of the Involuntary Transfer Notice. If the Company does not elect to purchase all of the
Involuntary Transfer Shares, the Company shall, within five (5) days after the expiration of the thirty (30) day notice period specified above, provide each Major Holder with written notice of such election, which notice shall include a
copy of the Involuntary Transfer Notice. Each Major Holder shall then have the right, exercisable within thirty (30) days following receipt of such notice, to purchase up to that number of the Involuntary Transfer Shares that the Company
elected not to purchase (all such remaining shares being referred to as the “Remaining Involuntary Transfer Shares”) equal to the aggregate Remaining Involuntary Transfer Shares multiplied by such Major Holder’s Major
Holder ROFR Pro Rata Share. In the event that a Major Holder does not wish to purchase its full Major Holder ROFR Pro Rata Share, then any Major Holder who has elected to purchase its full Major Holder ROFR Pro Rata Share shall have the right to
purchase, on a pro rata basis with any other Major Holders who so elect, any Remaining Involuntary Transfer Shares not purchased. If any of the foregoing options are timely exercised, the Involuntary Transferee shall sell to the Company or the Major
Holders, as applicable, and the Company or the Major Holders, as applicable, shall purchase from the Involuntary Transferee, such Involuntary Transfer Shares for a purchase price equal to fifty percent (50%) of the Fair Market Value (as defined
below) of a single Involuntary Transfer Share as of the date of the Involuntary Transfer multiplied by the number of Involuntary Transfer Shares being purchased. At its option, the Company or any purchasing Major Holder may elect to purchase
Involuntary Transfer Shares by the delivery of a promissory note in a principal amount equal to the purchase price, which amount shall be payable in full no later than the second (2nd) anniversary of the issuance thereof and may be prepaid in whole or in part at any time at the option of the
maker. For the purposes of this Section 3.9, “Fair Market Value” means the fair market value of each Involuntary Transfer Share, as determined in good faith by the Board of Directors. The Company’s or the Major
Holder’s, as applicable, exercise notice shall specify the time, place and date for settlement of such purchase, which shall be consummated at a closing held within the time period specified above. If the Company and the Major Holders, on a
collective basis, do not elect to purchase all of the Involuntary Transfer Shares pursuant to and within the time periods set forth above, any remaining Involuntary Transfer Shares shall be Transferred to the Involuntary Transferee subject
thereafter to all provisions of this Agreement. 

  
 11 

 4. MISCELLANEOUS. 
 4.1 Legends. 
 (a) Concurrently with the execution of this
Agreement, there shall be imprinted or otherwise placed, on each certificate representing Stockholder Shares, the following restrictive legend (the “Legend”): 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A STOCKHOLDERS’ AGREEMENT WHICH PLACES
CERTAIN RESTRICTIONS ON THE SALE OR TRANSFER OF THE SHARES REPRESENTED HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH
STOCKHOLDERS’ AGREEMENT WILL BE FURNISHED TO THE RECORD HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS.” 

(b) The Company agrees that, during the term of this Agreement, it will not remove, and will not permit to be removed (upon
registration of transfer, reissuance or otherwise), the Legend from any certificate representing Stockholder Shares and will place or cause to be placed the Legend on any new certificate issued to represent Stockholders Shares theretofore
represented by a certificate carrying the Legend. 
 4.2 Successors. The applicable provisions of this Agreement shall be
binding upon the successors in interest to any of the Stockholder Shares. The Company shall not permit the Transfer of any of the Stockholder Shares on its books or issue a new certificate representing any of the Stockholder Shares unless and until
the person to whom such security is to be transferred shall have executed an Instrument of Accession in the form attached hereto as Exhibit F, pursuant to which such person becomes a party to this Agreement and agrees to be bound by all
the provisions hereof. 
 4.3 Specific Performance. The parties acknowledge and agree that it is impossible to measure in
money the damages which will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and therefore agree that the terms of this Agreement shall be
specifically enforceable. If any party hereto or its heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby
waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 12 

 4.4 Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.5 Amendment and Waiver. Any provision of this Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Majority Investors. Notwithstanding the foregoing: (i) this Agreement may be amended only with the written
consent of the Company for the sole purpose of including Additional Holders as “Series C Preferred Holders,” “Series B Preferred Holders,” “Series A Preferred Holders,” “Series A-1 Preferred
Holders” or “Common Holders” hereunder; (ii) this Agreement may be amended only with the written consent of the Company for the sole purpose of including additional purchasers of Series C Preferred Stock as
“Series C Preferred Holders” hereunder, additional purchasers of Series B Preferred Stock as “Series B Preferred Holders” hereunder or additional purchasers of Series A Preferred Stock as “Series A
Preferred Holders” hereunder; and (iii) this Agreement may not be amended or terminated and the observance of any term of this Agreement may not be waived with respect to any Stockholder without the written consent of such Stockholder
unless such amendment, termination or waiver applies to all Stockholders in the same fashion. 
 4.6 Notices. All notices
required in connection with this Agreement shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by electronic mail or confirmed facsimile, if sent during normal
business hours of the recipient; if not, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with
a nationally recognized overnight courier, specifying next day delivery, with written notification of receipt. All communications shall be sent to the holder appearing on the books of the Company or at such address as such party may designate by ten
(10) days advance written notice to the other parties hereto. 
 4.7 Severability. If one or more provisions of this
Agreement are held by a court of competent jurisdiction to be unenforceable under applicable legal requirements, the parties agree to promptly renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement in writing for such provision, then: (i) such provision shall be excluded from this Agreement; (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded; and (iii) the
balance of this Agreement shall be enforceable in accordance with its terms. 
 4.8 Governing Law. This Agreement shall
be governed by and construed in accordance with the General Corporation Law of the State of Delaware without reference to its principles of conflict of laws. 
 4.9 Entire Agreement. This Agreement, together with the exhibits and schedules hereto, constitutes the entire agreement among the parties, and no party shall be liable or bound to any other party
in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 

  
 13 

 4.10 Counterparts; Execution by Facsimile. This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile (or similar electronic means) shall be equally
as effective as delivery of an original executed counterpart of this Agreement. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 14 

 
			
	STOCKHOLDER:
	
	AVALON VENTURES IX, L.P.
		
	By:	 	Avalon Ventures IX GP, LLC
	Its:	 	General Partner
	
	 /s/ Jay Lichter

	Name:	 	Jay Lichter
	Title:	 	Managing Member
		
	Address:	 	1134 Kline Street
		 	La Jolla, CA 92037
	
	STOCKHOLDER:
	
	MPM BIOVENTURES V, L.P.
		
	By:	 	MPM BioVentures V GP LLC
	Its:	 	General Partner
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Managing Member
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116
	
	MPM ASSET MANAGEMENT INVESTORS
	BV5 LLC
		
	By:	 	MPM BioVentures V LLC
	Its:	 	Manager
	
	 /s/ John Vander Vort

	Name:	 	John Vander Vort
	Title:	 	Member
		
	Address:	 	200 Clarendon St. 54F
		 	Boston, MA 02116

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 MIDPOINT FOOD & AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian
		 	Carmel, IN 46033
	
	STOCKHOLDER:
	
	 MIDPOINT FOOD & AG

	 CO-INVESTMENT FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ R. Meeusen

	(signature)
		
	Print Name:	 	 R. Meeusen

	Title:	 	 Partner

	(if applicable)
		
	Address:	 	11550 N. Meridian St.
		 	Carmel, IN 46032
	
	STOCKHOLDER:
	
	 EWING MARION KAUFFMAN

	 FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ Kristen Bechard

	(signature)
		
	Print Name:	 	 Kristen Bechard

	Title:	 	 Controller

	(if applicable)
		
	Address:	 	4801 Rockhill Road
		 	Kansas City, MO 64110

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 HALL FAMILY FOUNDATION

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 VP &Treasurer

	(if applicable)
		
	Address:	 	P.O. Box 419580
		 	Maildrop 323
		 	Kansas City, MO 64141
	
	STOCKHOLDER:
	
	 MIDDLELAND AG FUND, LP

	(entity name if applicable)
		
	By:	 	 /s/ Brian Mixe

	(signature)
		
	Print Name:	 	 Brian Mixe

	Title:	 	 Manager, Middleland AG LLC, its

general partner

	(if applicable)
		
	Address:	 	888 16th St.
		 	Suite 800
		 	Washington, DC 20006

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 MID-AMERICA ANGELS INVESTMENTS,

LLC

	(entity name if applicable)
		
	By:	 	 /s/ Joel Wiggins

	(signature)
		
	Print Name:	 	 Joel Wiggins

	Title:	 	 Executive Manager

	(if applicable)
		
	Address:	 	8527 Bluejacket Street
		 	Lenexa, KS 66214
		 	PH: 913.438.2282
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William Gautreaux

	(signature)
		
	Print Name:	 	 William Gautreaux

	Title:	 	  

	(if applicable)
		
	Address:	 	200 W 54th St.
		 	Kansas City, MO 64112
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Irv Hockaday

	(signature)
		
	Print Name:	 	 Irv Hockaday

	Title:	 	  

	(if applicable)
		
	Address:	 	2600 Grand Ave.
		 	Suite 450
		 	Kansas City, MO 64108

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 GRASSMERE KANSAS ANGEL

INVESTMENTS, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Peter C. Brown

	(signature)
		
	Print Name:	 	 Peter C. Brown

	Title:	 	 Chairman

	(if applicable)
		
	Address:	 	801 W. 47th St., Suite 400
		 	Kansas City, MO 64112
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ David Frantze

	(signature)
		
	Print Name:	 	 David Frantze

	Title:	 	  

	(if applicable)
		
	Address:	 	2200 W. 125th St.
		 	Leawood, KS 66209
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Stephen A. Lightstone

	(signature)
		
	Print Name:	 	 Stephen A. Lightstone

	Title:	 	  

	(if applicable)
		
	Address:	 	4935 Central St.
		 	Kansas City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Michael A. Driscoll

	(signature)
		
	Print Name:	 	 Michael A. Driscoll

	Title:	 	  

	(if applicable)
		
	Address:	 	823 Woodland Ave
		 	Oradell, NJ 07649
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Chris McGrath

	(signature)
		
	Print Name:	 	 Chris McGrath

	Title:	 	  

	(if applicable)
		
	Address:	 	5078 Seashell Place
		 	San Diego, CA 92130
	
	STOCKHOLDER:
	
	 LIMIT &CO

	(entity name if applicable)
		
	By:	 	 /s/ John A. MacDonald

	(signature)
		
	Print Name:	 	 John A. MacDonald

	Title:	 	 General Partner

	(if applicable)
		
	Address:	 	Chinquapin Trust Co.
		 	P.O. Box 419580, Mail Drop 323
		 	Kansas City, MO 64141

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 VIE VENTURE LLC

	(entity name if applicable)
		
	By:	 	 /s/ Steven St. Peter

	(signature)
		
	Print Name:	 	 Steven St. Peter

	Title:	 	 Member

	(if applicable)
		
	Address:	 	1901 Olathe Blvd
		 	Kansas City, KS 66103
	
	STOCKHOLDER:
	
	 THE SANCHEZ FAMILY TRUST,

MARCH 31, 2011, CARL SANCHEZ AND

ANGELA ROMERO SANCHEZ,
 TRUSTEES

	(entity name if applicable)
		
	By:	 	 /s/ Carl Sanchez

	(signature)
		
	Print Name:	 	 Carl Sanchez

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	1318 Summit Avenue
		 	Cardiff, CA 92007
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Robert F. Willamson

	(signature)
		
	Print Name:	 	 Robert F. Willamson

	Title:	 	  

	(if applicable)
		
	Address:	 	140 La Salle Ave
		 	Piedmont, CA 94610

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Eric I. Richman

	(signature)
		
	Print Name:	 	 Eric I. Richman

	Title:	 	  

	(if applicable)
		
	Address:	 	9740 Sorrel Ave
		 	Potomac, MD 20854
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ William F. Hartfiel III

	(signature)
		
	Print Name:	 	 William F. Hartfiel III

	Title:	 	  

	(if applicable)
		
	Address:	 	2732 Thomas Ave South
		 	Minneapolis, MN 55416
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Richard A. Sapp

	(signature)
		
	Print Name:	 	 Richard A. Sapp

	Title:	 	  

	(if applicable)
		
	Address:	 	PO Box 1514
		 	Rancho Santa Fe, CA 92067-1514

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Sanford J. Madigan

	(signature)
		
	Print Name:	 	 Sanford J. Madigan

	Title:	 	  

	(if applicable)
		
	Address:	 	12577 Kingspine Ave
		 	San Diego, CA 92131
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Gary William Pace

	(signature)
		
	Print Name:	 	 Gary William Pace

	Title:	 	  

	(if applicable)
		
	Address:	 	1405 Inspiration Dr.
		 	La Jolla, CA 92037
	
	STOCKHOLDER:
	
	 CURTIS A. KRIZEK REVOCABLE

TRUST, UTA DTD 12/17/98

	(entity name if applicable)
		
	By:	 	 /s/ Curtis A. Krizek

	(signature)
		
	Print Name:	 	 Curtis A. Krizek

	Title:	 	 Trustee

	(if applicable)
		
	Address:	 	4900 Main Street, Suite 700
		 	Kansas City, MO 64112

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Andrew S. Klocke

	(signature)
		
	Print Name:	 	 Andrew S. Klocke

	Title:	 	  

	(if applicable)
		
	Address:	 	8016 Cherokee Lane
		 	Leawood, KS 66206
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ John Neil

	(signature)
		
	Print Name:	 	 John Neil

	Title:	 	  

	(if applicable)
		
	Address:	 	7445 East Butler Drive
		 	Scottsdale, AZ 85258
	
	STOCKHOLDER:
	
	 MVA CAPITAL GROUP, LLC

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 Managing Member

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd. #307
		 	Wichita, KS 67206

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	 KANSAS CENTER FOR

	 ENTREPRENEURSHIP

	(entity name if applicable)
		
	By:	 	 /s/ Patricia L. Brasted

	(signature)
		
	Print Name:	 	 Patricia L. Brasted

	Title:	 	 President and CEO of Wichita

		 	 Technology Corporation

	(if applicable)
		
	Address:	 	7829 E. Rockhill Rd., Suite 307
		 	Wichita, KS 67206
	
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ David K. Rosen

	(signature)
		
	Print Name:	 	 David K. Rosen

	Title:	 	  

	(if applicable)
		
	Address:	 	85 Kendal Court
		 	Guilford, CT 06437
	
	STOCKHOLDER:
	
	STEVEN ST. PETER
	
	 /s/ Steven St. Peter

		
	Address:	 	43 Union Park #2
		 	Boston, MA 02118

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 
			
	STOCKHOLDER:
	
	  

	(entity name if applicable)
		
	By:	 	 /s/ Linda Rhodes

	(signature)
		
	Print Name:	 	 Linda Rhodes

	Title:	 	 Chief Scientific Officer

	(if applicable)
		
	Address:	 	3 White Birch Ln
		 	Holmdel, NJ 07733

 [SIGNATURE PAGE TO 
 SECOND AMENDED AND RESTATED STOCKHOLDER’S AGREEMENT] 

 EXHIBIT A 

SERIES C PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 
 MPM Bio Ventures V, L.P. 

MPM Asset Management Investors BV5 LLC 

MidPoint Food & Ag Fund, LP 

MidPoint Food & Ag Co-Investment Fund, LP 
 Hall Family Foundation 
 Middleland AG Fund, LP 

Mid-America Angels Investments, LLC 
 William
Gautreaux 
 Irv Hockaday 
 Grassmere
Kansas Angel Investments, LLC 
 David W. Frantze 
 Stephen A. Lightstone 
 Michael A. Driscoll 

Christopher H. McGrath 
 Limit &
Co. 
 Vie Venture LLC 
 The Sanchez
Family Trust, March 31, 2011, Carl Sanchez and Angela Romero Sanchez, 
 Trustees 
 Robert F. Williamson 
 Eric I. Richman 

William F. Hartfiel III 
 Richard A.
Sapp 

 Sanford J. Madigan 
 Gary William Pace 
 Curtis A. Krizek Revocable Trust UTA Dtd 12/17/98 

Andrew S. Klocke 
 John Neil 

Ewing Marion Kauffman Foundation 

 EXHIBIT B 

SERIES B PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 
 MPM BioVentures V, L.P. 

MPM Asset Management Investors BV5 LLC 

MidPoint Food & Ag Fund, LP 
 MidPoint
Food & Ag Co-Investment Fund, LP 
 Kansas Bioscience Authority 
 Ewing Marion Kauffman Foundation 
 Hall Family Foundation 

Middleland AG Fund, LP 
 Mid-America
Angels Investments, LLC 
 MVA Capital Group LLC 
 Paul DeBruce 
 Christena Gautreaux 
 Irv Hockaday 
 Grassmere Kansas Angel Investments, LLC 

Brian N. Kaufman 
 David W. Frantze

 The Maichen Family Trust Dated 7/13/99 
 Stephen A. Lightstone 
 John Neil 
 Michael A. Driscoll 
 Sheila Kemper Dietrich IRA 

Christopher H. McGrath 
 Kansas Center for
Entrepreneurship, Inc. 

 EXHIBIT C 

SERIES A PREFERRED HOLDERS 
 Avalon Ventures IX, L.P. 
 MPM BioVentures V, L.P. 

MPM Asset Management Investors BV5 LLC 

MidPoint Food & Ag Fund, LP 
 MidPoint
Food & Ag Co-Investment Fund, LP 
 Kansas Bioscience Authority 

 EXHIBIT D 

SERIES A-1 PREFERRED HOLDERS 
 RaQualia Pharma Inc. 

 EXHIBIT E 

COMMON HOLDERS 

David K. Rosen 
 MPM BioVentures V,
L.P. 
 MPM Asset Management Investors BV5 LLC 
 Steven St. Peter 
 Louis Mawhinney 
 Linda Rhodes 
 Bill Zollers 
 Lesley Rausch-Derra 
 Michele Gallucci 

 EXHIBIT F 

INSTRUMENT OF ACCESSION 
 The undersigned,                     , as a condition precedent to becoming the owner or holder of
record of                     (            ) shares of
            stock of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to become a
“                    Holder” under that certain Second Amended and Restated Stockholders’ Agreement, dated as of December 28,
2012 (the “Stockholders’ Agreement”), by and among the Company and the parties named therein. This Instrument of Accession shall take effect and shall become an integral part of, and the undersigned shall become a party
to and bound by, the Stockholders’ Agreement immediately upon execution and delivery to the Company of this Instrument. 

IN WITNESS WHEREOF, this INSTRUMENT OF ACCESSION has been duly executed by or on behalf of the undersigned, as a sealed instrument under
the laws of the State of Delaware, as of the date below written. 
  

			
	Signature:
	
	  

		
	(Print Name)	 	  

 

			
	
	Address:
	
	  

	
	  

		
	Date:	 	  

	
	Accepted:
	
	ARATANA THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
		
	Date:EX-10.3

 Exhibit 10.3 
 FORM OF 
 INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of
[            ] [    ], 20[    ], by and among Aratana Therapeutics, Inc. (the “Company”) and
[            ] (the “Indemnitee”). 

RECITALS 

WHEREAS, the Company values Indemnitee’s service to the Company as a director or officer and desires that Indemnitee continue
to serve the Company in such capacity; 
 WHEREAS, Indemnitee does not regard the protection available under the
organizational documents of the Company and any insurance policies maintained by the Company as adequate in the present circumstances, and Indemnitee may not be willing to continue to serve in his capacity as a director or officer of the Company
without the additional protections set forth in this Agreement; 
 WHEREAS, the Board of Directors of the Company (the
“Board”) has determined that, on the basis of the foregoing, it is reasonable, prudent and necessary for the Company to obligate itself contractually to indemnify, and to advance expenses on behalf of, Indemnitee to the
fullest extent permitted by applicable law so that Indemnitee will serve or continue to serve the Company free from undue concern that he will not be so indemnified; 
 WHEREAS, this Agreement is a supplement to and in furtherance of the organizational documents of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute
therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 
 WHEREAS, Indemnitee may have certain
rights to indemnification and/or insurance provided by an investment or venture capital fund with which Indemnitee is or may become affiliated (the “Associated Fund”) which Indemnitee and the Associated Fund intend to be
secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company’s acknowledgement and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve on the Board.

 NOW, THEREFORE, in consideration of the mutual promises and agreements herein contained, and intending to be legally
bound, the parties hereto agree as follows: 
 AGREEMENT 
 1.     INDEMNIFICATION OF INDEMNITEE AND ASSOCIATED FUND. The Company
hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof:

  

 (a) Indemnitee shall be entitled to the rights of indemnification provided in this
Section 1(a) if, by reason of his Corporate Status (as defined in Section 13(c)), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as defined in Section 13(i)) other
than a Proceeding by or in the right of the Company. Pursuant to this Section 1(a), Indemnitee shall be indemnified against all Expenses (as defined in Section 13(g)), judgments, penalties, fines and amounts paid in
settlement actually and reasonably incurred by him, or on his behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not
opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful. 
 (b) Indemnitee shall be entitled to the rights of indemnification provided in this Section 1(b) if, by reason of his Corporate Status, the Indemnitee is, or is threatened to be made, a
party to or participant in any Proceeding brought by or in the right of the Company. Pursuant to this Section 1(b), Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the
Indemnitee’s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, that
if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent
that a court of competent jurisdiction shall determine that such indemnification may be made. 
 (c) Notwithstanding any
other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as
such may be amended from time to time, against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as
to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim,
issue or matter. For purposes of this Section 1(c) and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such
claim, issue or matter. 
 (d) If the Associated Fund is, or is threatened to be made, a party to or a participant in any
Proceeding relating to or arising by reason of the Associated Fund’s position as a stockholder of, or lender to, the Company, or the Associated Fund’s appointment of or affiliation with Indemnitee or any other director, including without
limitation any alleged misappropriation of a Company asset or corporate opportunity, any claim of misappropriation or infringement of intellectual property relating to the Company, any alleged false or misleading statement or omission made by the
Company (or on its behalf) or its employees or agents, or any allegation of inappropriate control or influence over the Company or its Board members, officers, equity holders or debt holders, then the Associated Fund will be entitled to
indemnification hereunder for Expenses to the same extent as Indemnitee, and the terms of this Agreement as they relate to procedures for indemnification of Indemnitee and advancement of Expenses shall apply to any such indemnification of the
Associated Fund. The rights provided to the Associated Fund under 

  
 2 

 
this Section 1(d) shall: (i) be suspended during any period during which the Associated Fund does not have a representative on the Board; and (ii) terminate on an initial
public offering of the Company’s Common Stock under the Securities Act of 1933, as amended (an “IPO”); provided, however, that in the event of any such suspension or termination, the Associated Fund’s
rights to indemnification will not be suspended or terminated with respect to any Proceeding based in whole or in part on facts and circumstances occurring at any time prior to such suspension or termination regardless of whether the Proceeding
arises before or after such suspension or termination. The Company and Indemnitee agree that the Associated Fund is an express third party beneficiary of the terms of this Section 1(d). 

2.     ADDITIONAL INDEMNITY. In addition to, and without
regard to any limitations on, the indemnification provided for in Section 1 of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in
settlement actually and reasonably incurred by him or on his behalf if, by reason of his Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company),
including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company’s obligations pursuant to this Agreement shall be that the Company
shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Sections 6 and 7 hereof) to be unlawful. 

 

	3.	CONTRIBUTION. 

 (a) Whether or not the indemnification provided in Sections 1 and 2 hereof is available, in respect of any Proceeding in which the Company is jointly liable with Indemnitee (or
would be if joined in such Proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and
relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such
settlement provides for a full and final release of all claims asserted against Indemnitee. 
 (b) Without diminishing or
impairing the obligations of the Company set forth in Section 3(a), if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in
proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and
Indemnitee, on the other hand, from the transaction from which such Proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further
adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and

  
 3 

 
Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which the Law
may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and
Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and
the degree to which their conduct is active or passive. 
 (c) The Company hereby agrees to fully indemnify and hold
Indemnitee harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee. 

(d) To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable
to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or
for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect: (i) the
relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and
Indemnitee in connection with such event(s) and/or transaction(s). 
 4.     INDEMNIFICATION
FOR EXPENSES OF A WITNESS. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a
witness, or is made (or asked to) respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 5.     ADVANCEMENT OF EXPENSES. Notwithstanding
any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within thirty (30) days after the receipt by
the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses
incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified
against such Expenses. Any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest free. 

6.     PROCEDURES AND PRESUMPTIONS FOR
DETERMINING ENTITLEMENT TO INDEMNIFICATION. It is the intent of this Agreement to secure for Indemnitee rights of indemnification that are as favorable as may be
permitted under applicable law. Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement: 

  
 4 

 (a) To obtain indemnification under this Agreement, Indemnitee shall submit to the
Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The
Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a
request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of
the Company. 
 (b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of
Section 6(a) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board: (i) by a majority vote
of the Disinterested Directors (as defined in Section 13(d)), even though less than a quorum; (ii) by a committee of those Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a
quorum; (iii) if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (iv) if so directed by
the Board, by the stockholders of the Company; provided, however, that, notwithstanding the foregoing, any determination with respect to Indemnitee’s entitlement to indemnification hereunder that is made at any time following the
consummation of a Change in Control (as defined in Section 13(b)) that occurs at any time when the Company has a class of securities registered under the Exchange Act (as defined in Section 13(f))or following the consummation
of an IPO shall be made solely by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. 
 (c) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this
Section 6(c). The Independent Counsel shall be selected by the Board. Indemnitee may, within 10 days after such written notice of selection shall have been given, deliver to the Company a written objection to such selection;
provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 13(h) of this
Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the
Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written
request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection
which shall have been made by the Indemnitee to the Company’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the
person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 6(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by
such Independent Counsel in connection with acting pursuant to Section 6(b) hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section 6(c), regardless of the manner in which such
Independent Counsel was selected or appointed. 

  
 5 

 (d) In making a determination with respect to entitlement to indemnification
hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of
persuasion by clear and convincing evidence. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that
indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such
applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 
 (e) Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise (as defined in Section 13(e)),
including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the
Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of
the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(e) are satisfied, it shall in any event be
presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the
burden of persuasion by clear and convincing evidence. 
 (f) If the person, persons or entity empowered or selected
under this Section 6 to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of
entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent: (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make
Indemnitee’s statement not materially misleading, in connection with the request for indemnification; or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be
extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or
evaluate documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 6(f) shall not apply if the determination of entitlement to indemnification is to be made by
the stockholders pursuant to Section 6(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate,
resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat or (B) a special meeting of
stockholders is called within fifteen 

  
 6 

 
(15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such
determination is made thereat. 
 (g) Indemnitee shall cooperate with the person, persons or entity making such
determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected
from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a
determination regarding the Indemnitee’s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity
making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

(h) The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a
party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation,
settlement of such Proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding. Anyone seeking to overcome this presumption shall have the
burden of proof and the burden of persuasion by clear and convincing evidence. 
 (i) The termination of any Proceeding
or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of
Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding,
that Indemnitee had reasonable cause to believe that his conduct was unlawful. 
  

	7.	REMEDIES OF INDEMNITEE. 

(a) In the event that: (i) a determination is made pursuant to Section 6 of this Agreement that Indemnitee is not
entitled to indemnification under this Agreement; (ii) advancement of Expenses is not timely made pursuant to Section 5 of this Agreement; (iii) no determination of entitlement to indemnification is made pursuant to
Section 6(b) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification; (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after
receipt by the Company of a written request therefor; or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to
have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication in any court of competent jurisdiction of Indemnitee’s entitlement to such indemnification. Indemnitee

  
 7 

 
shall commence such proceeding seeking an adjudication within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to
this Section 7(a). The Company shall not oppose Indemnitee’s right to seek any such adjudication. 
 (b)
In the event that a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 7 shall be
conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under Section 6(b). 
 (c) If a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination
in any judicial proceeding commenced pursuant to this Section 7, absent: (i) a misstatement by Indemnitee of a material fact or an omission of a material fact necessary to make Indemnitee’s misstatement not materially
misleading in connection with the application for indemnification; or (ii) a prohibition of such indemnification under applicable law. 
 (d) In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of his rights under, or to recover damages for breach of, this Agreement, or to recover under
any directors’ and officers’ liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types described in the definition of “Expenses” in
Section 13(d) of this Agreement) actually and reasonably incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or
insurance recovery. 
 (e) The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to
this Section 7 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. The Company shall
indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such expenses to
Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance
policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. 

(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this
Agreement shall be required to be made prior to the final disposition of the Proceeding. 
  

	8.	NON-EXCLUSIVITY, SURVIVAL OF RIGHTS, ETC. 

(a) The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which
Indemnitee may at any time be entitled under applicable 

  
 8 

 
law, the organizational documents of the Company, any other agreement with the Company, a vote of the Company’s stockholders, a resolution of the Board or otherwise. No amendment, alteration
or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or
repeal. To the extent that a change in any applicable law, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Company’s organizational documents and this Agreement, it is the
intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and
remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy. 
 (b) To the extent that the Company maintains an
insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their
terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has
directors’ and officers’ liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 

(c) The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of expenses and/or
insurance provided by the Associated Fund and/or certain of its affiliates (collectively, the “Additional Indemnitors”). The Company hereby agrees that: (i) it is the indemnitor of first resort (i.e., its obligations to
Indemnitee are primary and any obligation of the Additional Indemnitors (or any insurance carrier providing insurance coverage purchased by any Additional Indemnitor) to advance expenses or to provide indemnification for the same expenses or
liabilities incurred by Indemnitee are secondary); (ii) it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in
settlement to the extent legally permitted and as required by the terms of this Agreement and the organizational documents of the Company, without regard to any rights Indemnitee may have against the Additional Indemnitors (or any insurance carrier
providing insurance coverage purchased by any Additional Indemnitor); and (iii) it irrevocably waives, relinquishes and releases the Additional Indemnitors from any and all claims against the Additional Indemnitors for contribution, subrogation
or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Additional Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the
Company shall affect the foregoing and the Additional Indemnitors shall have a right of indemnification and/or be subrogated to the full extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The
Company and Indemnitee agree that the Additional Indemnitors are express third party beneficiaries of the terms of this Section 8(c). 

  
 9 

 (d) Except as provided in Section 8(c) above, in the event of any payment
under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee (other than against the Additional Indemnitors), who shall execute all papers required and take all action necessary
to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. 
 (e) Except as provided in Section 8(c) above, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent
that Indemnitee has otherwise actually received payment of such amounts under any insurance policy, contract, other agreement or otherwise. 
 (f) Except as provided in Section 8(c) above, the Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company
as a director, officer, employee or agent of any Enterprise other than the Company shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other Enterprise. 

9.     EXCEPTION TO RIGHT OF INDEMNIFICATION.
Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to provide any indemnification in connection with any claim made against Indemnitee: (i) for which payment has actually been made to or
on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision, provided that the foregoing shall not affect the
rights of Indemnitee or the Additional Indemnitors set forth Section 8(c); (ii) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of
Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law; or (iii) in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any
Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (A) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (B) the Company
provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. 
 10.
    DURATION OF AGREEMENT. All agreements and obligations of the Company contained herein shall continue until the date that is six (6) years after the date upon which
Indemnitee’s Corporate Status terminates and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under Section 7 hereof) by reason of his Corporate Status, whether or not
he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and
personal and legal representatives. 

  
 10 

 11.    SECURITY. To the extent requested by
Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any
such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee. 

12.    ENFORCEMENT. The Company expressly confirms and agrees that it has entered into this
Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or
director of the Company. The Company shall not seek from a court, or agree to, a “bar order” that would have the effect of prohibiting or limiting Indemnitee’s rights to receive advancement of Expenses under this Agreement.

  

	13.	DEFINITIONS. For purposes of this Agreement: 

(a) “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act;
provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity. 

(b) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of
any of the following events: 
 (i) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities
of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities; 
 (ii) during any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board,
and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 13(a)(i), (a)(iii) or (a)(iv)) whose election by the Board
or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election
was previously so approved, cease for any reason to constitute a least a majority of the members of the Board; 
 (iii)
the effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty-one percent (51%) of the combined voting power of the voting securities of the surviving entity
outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the Board or other governing body of such surviving entity; 

  
 11 

 (iv) the approval by the stockholders of the Company of a complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; or 

(v) there occurs any other event of a nature that would be required to be reported in response to Item 6(e) of
Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement. 

(c) “Corporate Status” describes the status of a person who is or was at any time (including, without
limitation, any time prior to the date of this Agreement) a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is
or was serving at the express written request of the Company. 
 (d) “Disinterested Director”
means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. 
 (e) “Enterprise” shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was
serving at the express written request of the Company as a director, officer, employee, agent or fiduciary. 
 (f)
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 (g)
“Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges,
postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness
in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign
taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal
bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 
 (h) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years
has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification
agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable
standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable
fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

  
 12 

 (i) “Person” shall have the meaning as set forth in
Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude: (i) the Company; (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company; and
(iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 
 (j) “Proceeding” includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative
hearing or any other actual, threatened or completed proceeding (including one pending on or before the date of this Agreement but excluding one initiated by an Indemnitee pursuant to Section 7 of this Agreement to enforce his rights
under this Agreement), whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of the fact that
Indemnitee is or was an officer or director of the Company, by reason of any action taken by him or of any inaction on his part while acting as an officer or director of the Company, or by reason of the fact that he is or was serving at the request
of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise, in each case whether or not he is acting or serving in any such capacity at the time any liability or
expense is incurred for which indemnification can be provided under this Agreement. 

14.    SEVERABILITY. The invalidity or unenforceability of any provision hereof shall in
no way affect the validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In
the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict. 

15.    MODIFICATION AND WAIVER. No supplement,
modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

16.    NOTICE BY INDEMNITEE. Indemnitee agrees to promptly
notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered
hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the
Company. 
 17.    NOTICES. All notices and other communications given or made
pursuant to this Agreement shall be in writing and shall be deemed effectively given: (i) upon personal delivery 

  
 13 

 
to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next
business day; (iii) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent: 
 (a) To Indemnitee at the address set forth below Indemnitee’s signature hereto. 
 (b) To the Company at: 
   Aratana Therapeutics, Inc. 

  1901 Olathe Boulevard 
   Kansas City, KS 66103 
   Attention: Board of Directors

 or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

 18.    HEADINGS. The headings of the paragraphs of this Agreement are inserted for
convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 

19.    GOVERNING LAW. This Agreement and the legal relations among the parties
shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules 
 20.    ENTIRE AGREEMENT. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject
matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof 
 21.    COUNTERPARTS. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature (or other similar electronic means) and in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]